Cofilin Drives Cell-invasive and Metastatic Responses to TGF-β in Prostate Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2014 Feb 11

PMID 24509905

Citations 56

Authors

Joanne Collazo

Beibei Zhu

Spencer Larkin

Sarah K Martin

Hong Pu

Craig Horbinski

Shahriar Koochekpour

Natasha Kyprianou

Affiliations

Soon will be listed here.

Abstract

Cofilin (CFL) is an F-actin-severing protein required for the cytoskeleton reorganization and filopodia formation, which drives cell migration. CFL binding and severing of F-actin is controlled by Ser3 phosphorylation, but the contributions of this step to cell migration during invasion and metastasis of cancer cells are unclear. In this study, we addressed the question in prostate cancer cells, including the response to TGF-β, a critical regulator of migration. In cells expressing wild-type CFL, TGF-β treatment increased LIMK-2 activity and cofilin phosphorylation, decreasing filopodia formation. Conversely, constitutively active CFL (SerAla) promoted filipodia formation and cell migration mediated by TGF-β. Notably, in cocultures of prostate cancer epithelial cells and cancer-associated fibroblasts, active CFL promoted invasive migration in response to TGF-β in the microenvironment. Further, constitutively active CFL elevated the metastatic ability of prostate cancer cells in vivo. We found that levels of active CFL correlated with metastasis in a mouse model of prostate tumor and that in human prostate cancer, CFL expression was increased significantly in metastatic tumors. Our findings show that the actin-severing protein CFL coordinates responses to TGF-β that are needed for invasive cancer migration and metastasis.

Citing Articles

Unleashing the power of peptides in prostate cancer immunotherapy: mechanism, facts and perspectives.

Li X, Yang F, Wang M, Huang X, Zeng X, Zhou L Front Pharmacol. 2025; 16:1478331.

PMID: 40078274 PMC: 11897510. DOI: 10.3389/fphar.2025.1478331.

Prostate Cancer: De-regulated Circular RNAs With Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Genomics Proteomics. 2025; 22(2):136-165.

PMID: 39993805 PMC: 11880926. DOI: 10.21873/cgp.20494.

Protein-Based Predictive Biomarkers to Personalize Neoadjuvant Therapy for Bladder Cancer-A Systematic Review of the Current Status.

Bedore S, van der Eerden J, Boghani F, Patel S, Yassin S, Aguilar K Int J Mol Sci. 2024; 25(18).

PMID: 39337385 PMC: 11432686. DOI: 10.3390/ijms25189899.

Role of actin-binding proteins in prostate cancer.

Fu F, Yu Y, Zou B, Long Y, Wu L, Yin J Front Cell Dev Biol. 2024; 12:1430386.

PMID: 39055653 PMC: 11269120. DOI: 10.3389/fcell.2024.1430386.

CFL1 is Implicated in Chronic Myeloid Leukemia Response during Imatinib Therapy.

Yin X, Li X, Jiang H, Lin X, Ma Z, Chen X J Cancer. 2024; 15(8):2424-2430.

PMID: 38495482 PMC: 10937266. DOI: 10.7150/jca.92202.

References

Arnold J, Isaacs J . Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer. 2002; 9(1):61-73. PMC: 4124629. DOI: 10.1677/erc.0.0090061. View

Wang W, Mouneimne G, Sidani M, Wyckoff J, Chen X, Makris A . The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol. 2006; 173(3):395-404. PMC: 2063840. DOI: 10.1083/jcb.200510115. View

Nasu Y, Timme T, Yang G, Bangma C, Li L, Ren C . Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med. 1998; 4(9):1062-4. DOI: 10.1038/2048. View

Van Troys M, Huyck L, Leyman S, Dhaese S, Vandekerkhove J, Ampe C . Ins and outs of ADF/cofilin activity and regulation. Eur J Cell Biol. 2008; 87(8-9):649-67. DOI: 10.1016/j.ejcb.2008.04.001. View

Davila M, Frost A, Grizzle W, Chakrabarti R . LIM kinase 1 is essential for the invasive growth of prostate epithelial cells: implications in prostate cancer. J Biol Chem. 2003; 278(38):36868-75. DOI: 10.1074/jbc.M306196200. View

Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Holtta E . TGF-β signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol. 2012; 181(6):2202-16. DOI: 10.1016/j.ajpath.2012.08.027. View

Mouneimne G, DesMarais V, Sidani M, Scemes E, Wang W, Song X . Spatial and temporal control of cofilin activity is required for directional sensing during chemotaxis. Curr Biol. 2006; 16(22):2193-205. DOI: 10.1016/j.cub.2006.09.016. View

Pu H, Collazo J, Jones E, Gayheart D, Sakamoto S, Vogt A . Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res. 2009; 69(18):7366-74. PMC: 2747670. DOI: 10.1158/0008-5472.CAN-09-0758. View

Ono S . Mechanism of depolymerization and severing of actin filaments and its significance in cytoskeletal dynamics. Int Rev Cytol. 2007; 258:1-82. DOI: 10.1016/S0074-7696(07)58001-0. View

10.

Karantanos T, Thompson T . GEMMs shine a light on resistance to androgen deprivation therapy for prostate cancer. Cancer Cell. 2013; 24(1):11-3. PMC: 3881957. DOI: 10.1016/j.ccr.2013.06.007. View

11.

Steeg P . Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12(8):895-904. DOI: 10.1038/nm1469. View

12.

Teicher B . Transforming growth factor-beta and the immune response to malignant disease. Clin Cancer Res. 2007; 13(21):6247-51. DOI: 10.1158/1078-0432.CCR-07-1654. View

13.

Magnon C, Hall S, Lin J, Xue X, Gerber L, Freedland S . Autonomic nerve development contributes to prostate cancer progression. Science. 2013; 341(6142):1236361. DOI: 10.1126/science.1236361. View

14.

Olson M . Applications for ROCK kinase inhibition. Curr Opin Cell Biol. 2008; 20(2):242-8. PMC: 2377343. DOI: 10.1016/j.ceb.2008.01.002. View

15.

Guo Y, Kyprianou N . Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells. Cell Growth Differ. 1998; 9(2):185-93. View

16.

Arjonen A, Kaukonen R, Ivaska J . Filopodia and adhesion in cancer cell motility. Cell Adh Migr. 2011; 5(5):421-30. PMC: 3218609. DOI: 10.4161/cam.5.5.17723. View

17.

Umbas R, Schalken J, Aalders T, Carter B, Karthaus H, Schaafsma H . Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 1992; 52(18):5104-9. View

18.

Hotulainen P, Paunola E, Vartiainen M, Lappalainen P . Actin-depolymerizing factor and cofilin-1 play overlapping roles in promoting rapid F-actin depolymerization in mammalian nonmuscle cells. Mol Biol Cell. 2004; 16(2):649-64. PMC: 545901. DOI: 10.1091/mbc.e04-07-0555. View

19.

Sakamoto S, Kyprianou N . Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med. 2010; 31(2):205-14. PMC: 2988681. DOI: 10.1016/j.mam.2010.02.001. View

20.

Zhu H, Zhao J, Zhu B, Collazo J, Gal J, Shi P . EMMPRIN regulates cytoskeleton reorganization and cell adhesion in prostate cancer. Prostate. 2011; 72(1):72-81. PMC: 3158271. DOI: 10.1002/pros.21408. View